Linda Garland is an Oncology physician affiliated with University of Arizona. OpenAlex indexes 99 publications with 3,213 citations (h-index 27); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 N Campbell Ave
Tucson, AZ 857240001
Telephone
520-874-3500Registry record last updated 29 May 2008.
Clinical trials
- Liquid Biopsy for Early Non-small Lung Cancer Detection
Sponsor: University of Arizona
- Innovative Approach to Reduce Lung Cancer Stigma
Sponsor: University of Arizona
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20224 payments
- E.R. Squibb & Sons, L.L.C.Program year20221 payment
- Amgen Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
35.7%Kinase inhibitor35.7%Tagrisso38%Lorbrena19%Gilotrif18%Retevmo13%Alunbrig12%Part D<11 patientsMetabolism & gastrointestinal
19.8%Serotonin-3 Receptor Antagonist14.8%Ondansetron Hcl100%Part D≥35 patientsCorticosteroid4.9%Prednisone100%Part D<11 patientsNervous system
17.5%Phenothiazine17.5%Prochlorperazine Maleate100%Part D≥37 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2016–2021 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Alpert, MD
University of Arizona
Karl Kern, MD
University of Arizona
Peter Reaven, MD
University of Arizona
Alison Stopeck, MD
University of Arizona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”